References
- Piazza G, Fanikos J, Zayaruzny M, et al. Venous thromboembolic events in hospitalised medical patients. Thromb Haemost. 2009;102:505–510.
- Heit JA, Cohen AT, Andersen FA. Jr., Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood. 2005;910.
- Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41:3–14.
- Pengo V, Lensing AWA, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350:2257–2264.
- Prandoni P, et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997;82:423–428.
- Spyropoulos AC, Anderson FA, FitzGerald G, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011;140:706–714.
- Amin AN, Varker H, Princic N, et al. Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. J Hosp Med. 2012;7:231–238.
- Pendergraft T, Atwood M, Liu X, et al. Cost of venous thromboembolism in hospitalized medically ill patients. Am J Health Syst Pharm. 2013;70:1681–1687.
- Heit JA, Crusan DJ, Ashrani AA, et al. Effect of a near-universal hospitalization-based prophylaxis regimen on annual number of venous thromboembolism events in the US. Blood. 2017;130:109–114.
- Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368:513–523.
- Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365:2167–2177.
- Hull RD, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010;153:8–18.
- Weiss AJ, Elixhauser A, for Agency for Healthcare Research and Quality. Overview of hospital stays in the United States, 2012. 2014 [cited 2018 March 20]. Available from: https://www.hcup-us.ahrq.gov/reports/statbriefs/sb180-Hospitalizations-United-States-2012.pdf
- Organisation for Economic Co-operation and Development. Health at a glance 2017: OECD indicators. [cited 2018 March 20]. Available from: https://www.oecd-ilibrary.org/docserver/health_glance-2017-en.pdf?expires=1536312324&id=id&accname=guest&checksum=9A2183B01DA4247F63CA207618BB50BB
- US Department of Health and Human Services. CMS Statistics 2015. [cited 2018 May 24]. Available from: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/CMS-Statistics-Reference-Booklet/Downloads/2015CMSStatistics.pdf
- US Department of Health and Human Services. CMS Statistics 2016. [cited 2018 May 24]. Available from: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/CMS-Statistics-Reference-Booklet/Downloads/2016_CMS_Stats.pdf
- Agency for Healthcare Research and Quality, Rockville, MD. Statistical Brief #225: Healthcare Cost and Utilization Project (HCUP). 2017 [cited 2018 June 28]. Available from: www.hcup-us.ahrq.gov/reports/statbriefs/sb225-Inpatient-US-Stays-Trends.jsp.
- Jacobsen LA, Kent M, Lee M, et al. America’s aging population. Popul Bull. 2011;66(1):1–17. Available from: https://assets.prb.org/pdf11/aging-in-america.pdf (accessed 2018 June 28).
- Food and Drug Administration. FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients. [cited 2018 March 20]. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm564422.htm
- Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016;375:534–544.
- ASH Clinical Practice Guidelines on Venous Thromboembolism, 04-Feb-2019. [Online]. Available from: /VTE/. [Accessed: 26-Feb-2019].
- NICE. Clinical Guideline. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (Update) [Online]. 2017. Available from: https://www.nice.org.uk/guidance/indevelopment/gid-cgwave0795/consultation/html-content-2.
- Johnston A, Hsieh S-C, Carrier M, et al. A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: Implications for research and policy decision-making. PLoS One. 2018;13:e0207410.
- NICE. Venous thromboembolism: reducing the risk for patients in hospital: clinical guideline. 2010, 2015 [cited 2016 October 27]. Available from: nice.org.uk/guidance/cg92
- Centre for Reviews and Dissemination. Systematic reviews: CRD’s guidance for undertaking reviews in health care. 2009 [cited 2016 October 20]. Available from: https://www.york.ac.uk/media/crd/Systematic_Reviews.pdf
- Pharmaceutical Benefits Advisory Committee. Guidelines for preparing a submission to the PBAC. 2010 [cited 2017 June 26]. Available from: https://pbac.pbs.gov.au/content/information/files/pbac-guidelines-version-5.pdf
- Review Manager (RevMan). Version 5.3. Copenhagen (Denmark): The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.
- Higgins JPT, Altman DG, Sterne JAC, et al. Chapter 8: assessing risk of bias in included studies. In: Higgins JPT, Green S, Altman DG, et al, editors. Cochrane handbook for systematic reviews of interventions Version 5.1.0. 2011 [cited 2018 June 5]. Available from: www.handbook.cochrane.org
- Lunn DJ, Thomas A, Best N, et al. WinBUGS – a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput. 2000;10:325–337.
- RStudio Team. RStudio: integrated development for R. Boston (MA): RStudio, Inc; 2016. Available from: http://www.rstudio.com/.
- Sturtz S, Ligges U, Gelman A. R2WinBUGS: a package for running WinBUGS from R. J Stat Soft. 2005;12:1–16.
- Dias S, Welton NJ, Sutton AJ, et al. NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials; 2016 Sept [cited 2017 July 78]. Available from: http://scharr.dept.shef.ac.uk/nicedsu/wp-content/uploads/sites/7/2017/05/TSD2-General-meta-analysis-corrected-2Sep2016v2.pdf.
- Brooks S, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graphical Stat. 1998;7:434–455.
- Belch JJ, Lowe GD, Ward AG, et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J. 1981;26:115–117.
- Leizorovicz A, Cohen AT, Turpie AGG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874–879.
- Bergmann JF, Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness: the enoxaparin in medicine study group. Thromb Haemost. 1996;76:529–534.
- Mahé I, Bergmann JF, d’Azémar P, et al. Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study. Eur J Clin Pharmacol. 2005;61:347–351.
- Harenberg J, Roebruck P, Heene DL. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients: the heparin study in internal medicine group. Pathophysiol Haemos Thromb. 1996;26:127–139.
- Ishi SV, et al. Randomised controlled trial for efficacy of unfractionated heparin (UFH) versus low molecular weight heparin (LMWH) in thrombo-prophylaxis. J Assoc Phys India. 2013;61:882–886.
- Samama MM, Cohen AT, Darmon J-Y, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: prophylaxis in medical patients with enoxaparin study group. N Engl J Med. 1999;341:793–800.
- Kleber F-X, Witt C, Vogel G, et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J. 2003;145:614–621.
- Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Pathophysiol Haemos Thromb. 1996;26:49–56.
- Lederle FA, Sacks JM, Fiore L, et al. The prophylaxis of medical patients for thromboembolism pilot study. Am J Med. 2006;119:54–59.
- Schellong SM, Haas S, Greinacher A, et al. An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opin Pharmacother. 2010;11:2953–2961.
- Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332:325–329.
- Riess H, Haas S, Tebbe U, et al. A randomized, double-blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non-surgical patients: CERTIFY Study. J Thromb Haemost. 2010;8:1209–1215.
- Forette B, Wolmark Y. Calcium nadroparin in the prevention of thromboembolic disease in elderly subjects: Study of tolerance (translated by EMBASE). Presse Med. 1995;24:567–571.
- Kakkar AK, Cimminiello C, Goldhaber SZ, et al. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med. 2011;365:2463–2472.
- Lanitis T, Leipold R, Hamilton M, et al. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences. BMC Health Serv Res. 2017;17:74.
- Pesavento R, Prandoni P. Prevention and treatment of the post-thrombotic syndrome and of the chronic thromboembolic pulmonary hypertension. Expert Rev Cardiovasc Ther. 2015;13:193–207.
- Kelly J, Rudd A, Lewis RR, et al. Screening for subclinical deep-vein thrombosis. QJM. 2001;94:511–519.
- Dennis M, Mordi N, Graham C, et al. The timing, extent, progression and regression of deep vein thrombosis in immobile stroke patients: observational data from the CLOTS multicenter randomized trials. J Thromb Haemost. 2011;9:2193–2200.
- Vaitkus PT, Leizorovicz A, Cohen AT, et al. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost. 2005;93:76–79.
- Christensen MC, Mayer S, Ferran J-M. Quality of life after intracerebral hemorrhage: results of the factor seven for acute hemorrhagic stroke (FAST) trial. Stroke. 2009;40:1677–1682.
- Hütter BO, Gilsbach JM, Kreitschmann I. Quality of life and cognitive deficits after subarachnoid haemorrhage. Br J Neurosurg. 1995;9:465–476.
- Shah A, Shewale A, Hayes CJ, et al. Cost-effectiveness of oral anticoagulants for ischemic stroke prophylaxis among nonvalvular atrial fibrillation patients. Stroke. 2016;47:1555–1561.